These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34438020)

  • 41. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
    Ahn J; Peng S; Hung CF; Roden RBS; Best SR
    Laryngoscope; 2018 Jan; 128(1):E16-E20. PubMed ID: 28868617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
    Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
    Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
    Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
    Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.
    Chisholm CF; Kang TJ; Dong M; Lewis K; Namekar M; Lehrer AT; Randolph TW
    Eur J Pharm Biopharm; 2019 Mar; 136():213-220. PubMed ID: 30703544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.
    Uddin MN; Kouzi SA; Hussain MD
    J Pharm Pharm Sci; 2015; 18(2):220-34. PubMed ID: 26158287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines.
    Waheed MT; Thönes N; Müller M; Hassan SW; Razavi NM; Lössl E; Kaul HP; Lössl AG
    Transgenic Res; 2011 Apr; 20(2):271-82. PubMed ID: 20563641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
    Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
    PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.
    Garnock-Jones KP; Giuliano AR
    Drugs R D; 2012 Dec; 12(4):235-8. PubMed ID: 23017129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.
    Corbett HJ; Fernando GJ; Chen X; Frazer IH; Kendall MA
    PLoS One; 2010 Oct; 5(10):e13460. PubMed ID: 20976136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA; Perry CM
    Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.